Life Sciences

  • April 09, 2026

    Philly Injection Site Row Judge Rejects Nonprofit's 'Ploy'

    A Pennsylvania federal judge on Thursday called the addition of overdose prevention nonprofit Safehouse's president as a counterclaim plaintiff in the government's suit to stop it from launching a safe-injection site in Philadelphia a "ploy" to add another to the ranks of those claiming the government infringed the group's religious freedom.

  • April 09, 2026

    Abiomed Can't Escape Blood Pump Patent Case

    A Massachusetts federal judge has refused to let a Johnson & Johnson MedTech subsidiary dodge claims that it infringed a blood pump patent, the latest event in a wider legal battle launched against it by a unit of Swedish medical device company Getinge AB.

  • April 09, 2026

    Ecolab Says Personal Injury Law Firm Holding Back $148K

    Ecolab and its self-funded employee benefit plan have accused a North Carolina personal injury firm of withholding around $148,000 in settlement funds the food safety company says it's owed for covering a worker's medical bills after a car accident.

  • April 09, 2026

    Ex-Pharmacy Director Denies Using Trade Secrets At New Job

    A former director at a specialty infusion therapy pharmacy urged a New Jersey federal court to reject her former employer's bid to block her from working for a rival, arguing that her new job does not pose any threat of imminent harm to her former company.

  • April 09, 2026

    US Again Urges High Court To Back Drug Price Program

    The administration of President Donald Trump again urged the Supreme Court not to hear a challenge to the Medicare drug price negotiation program, arguing against a constitutional challenge brought by Boehringer Ingelheim that drug companies aren't forced to accept lower prices because they can choose not to participate. 

  • April 08, 2026

    Fed. Circ. Questions Specificity Needed In Oxy IP Invalidation

    A Federal Circuit panel expressed frustration with attorneys from both Purdue Pharma LP and generic-drug maker Accord Healthcare Inc. Wednesday as it tried to navigate whether the Delaware district court order invalidating Purdue's abuse-deterrence patent was explicit enough.

  • April 08, 2026

    Biz Judge Keeps Doc Class Action Against Luxottica, For Now

    A Texas Business Court judge Wednesday kept alive, on procedural grounds, a proposed class action made up of Texas optometrists who say that their office space deals with eye care giant Luxottica of America Inc. didn't follow Texas law.

  • April 08, 2026

    AbbVie Says 340B Program Defines 'Patient' Too Broadly

    Federally funded healthcare providers in the 340B Drug Pricing Program are using an "overly broad" interpretation of the word "patient" based on government guidelines, and it's leading to them abusing 340B discounts, AbbVie claimed in a lawsuit filed against two federal health agencies Wednesday.

  • April 08, 2026

    States Seek Time For Talks To Settle Drug Price-Fixing Suit

    The states suing generic-drug manufacturers in one of three sprawling antitrust cases want a Connecticut federal judge to pause all deadlines for three months so they can focus on settling with the remaining defendants, according to a joint filing.

  • April 08, 2026

    3M Settles Ex-Worker's COVID Vax Firing Suit

    A former 3M Co. employee who claimed the company's COVID-19 vaccination mandate policy was "unnecessary" and "draconian" has settled his more than 3-year-old suit over his firing, according to a court filing.

  • April 08, 2026

    AstraZeneca Wants 25 Opt-Ins Axed From Pay Bias Suit

    More than two dozen women refused to take part in required discovery and should be removed from a collective action accusing AstraZeneca of paying female pharmaceutical sales representatives less than men, the company told an Illinois federal court.

  • April 08, 2026

    Abbott Urges Ill. Jury To Reject Claims Formula Led To NEC

    Counsel for Abbott Laboratories told an Illinois jury Wednesday that four infants, whose mothers allege the company's preterm baby formula caused their serious intestinal illness, would have developed the disease "even without a drop of formula" given other risk factors and that the absence of other feeding options at the time of the babies' births dooms their parents' claims.

  • April 08, 2026

    Biopharma-Focused Jeito Wraps 2nd Fund With $1.2B In Tow

    Biopharmaceutical-focused private equity shop Jeito Capital, advised by Goodwin Procter LLP, on Wednesday announced that it closed its second fund above target after raising more than €1 billion ($1.2 billion) from investors.

  • April 08, 2026

    Faegre Drinker Hires 2 Venable FDA Partners In DC

    Faegre Drinker Biddle & Reath LLP has hired two attorneys from Venable LLP who joined that firm in 2023 and focus their practices on helping clients understand U.S. Food and Drug Administration regulatory frameworks, the firm announced Wednesday.

  • April 08, 2026

    Redesigned Supplement Partially Cleared In Patent Row

    A Delaware federal court has found that most of the redesigned versions of a nutritional supplement don't infringe a patent owned by Kaneka Corp., while also saying it's still unclear how much the Japanese company is owed for earlier versions the court found did infringe.

  • April 07, 2026

    Calif. Dialysis Bill Violates 1st Amendment, 9th Circ. Says

    The Ninth Circuit on Tuesday struck down provisions of a California law that aims to restrict dialysis providers' ability to profit from patients receiving health insurance premium assistance from nonprofit charities, ruling in a published opinion that the provisions violated nonprofit American Kidney Fund's and dialysis providers' First Amendment rights.

  • April 07, 2026

    Judge Says CPB Couldn't Void Harvard Researcher Visa

    A Vermont federal judge said Tuesday that a U.S. Customs and Border Protection officer at Logan Airport in Boston had no legal authority to cancel the visa of a Harvard researcher and Russian national after finding frog embryo samples in her luggage last year.

  • April 07, 2026

    NY Fertility Clinic Agrees To Settle Suit Over Destroyed Eggs

    Less than a month ahead of trial, a New York fertility clinic has agreed to resolve a suit accusing it of negligently allowing a woman's eggs to be destroyed due to alleged mishandling, according to documents filed in New York federal court.

  • April 07, 2026

    HHS Must Face States' Suit Over RFK's 'Dramatic Overhaul'

    A Rhode Island federal judge rejected Tuesday the government's bid to toss a group of states' lawsuit challenging Robert F. Kennedy Jr.'s "dramatic overhaul" of the U.S. Department of Health and Human Services, criticizing the government for rehashing jurisdictional arguments the court already rejected and finding the states' claims are plausible.

  • April 07, 2026

    Data Breach Counsel Chided For Flouting NC Court Rules

    Two attorneys looking to temporarily helm a series of putative data breach class actions targeting a radiology firm have failed to become interim co-lead class counsel, as a North Carolina Business Court judge chided them for not following rules and filing a procedurally deficient motion.

  • April 07, 2026

    Biogen, Investors Reach Deal In Alzheimer's Drug Litigation

    A class of investors has reached a deal with Biogen Inc. to avoid a trial and resolve a suit over statements executives made as they launched an Alzheimer's drug, according to a Tuesday filing in Massachusetts federal court.

  • April 07, 2026

    Minn. Can't Unfreeze $243M In Medicaid Funds, Judge Says

    A Minnesota federal judge on Monday denied the state's preliminary injunction request to release $243 million in Medicaid funds deferred by the federal government during a fraud investigation, holding that the "unprecedented" size and scope of the deferral action doesn't mean the Centers for Medicare & Medicaid Services isn't legally cleared to pursue the action.

  • April 07, 2026

    ImmunityBio Filmmaker Traded On Insider Tip, SEC Says

    A documentary filmmaker who worked for ImmunityBio Inc. will pay the U.S. Securities and Exchange Commission over $332,000 to end claims she scrambled to sell off her stake in the biotechnology company as it prepared to announce disappointing news about a pending drug application.

  • April 07, 2026

    Mich. AG Says PBMs Can't Stall Discovery In Drug-Pricing Suit

    Michigan's attorney general is urging a federal court to reject a renewed bid by pharmacy benefit managers to pause discovery in an antitrust case accusing them of price-fixing reimbursement rates, claiming the companies are relying on exaggerated burden claims and an ordinary motion to dismiss that is unlikely to succeed.

  • April 07, 2026

    Texas AG Says DOGE Data Led To Fraud Investigations

    The Texas attorney general on Tuesday announced investigations into dozens of Medicaid providers across Texas, claiming that data from the Department of Government Efficiency led to the fraud allegations.

Expert Analysis

  • AI Scientific Discovery Order Implications For Life Sciences

    Author Photo

    President Donald Trump's November executive order establishing a government effort to use artificial intelligence to accelerate scientific discovery has the potential to leverage significant federal resources and data to support research, drug and device approvals, and AI model training in the life sciences sector, say attorneys at Hogan Lovells.

  • What Rescheduling Means For Cannabis Labels, Marketing

    Author Photo

    The proposed reclassification of cannabis is expected to bring heightened scrutiny of labeling, advertising and marketing from the U.S. Food and Drug Administration and the Federal Trade Commission, but the brands that tighten evidence, standardize operations and professionalize marketing controls now will see fewer surprises and better outcomes, say attorneys at Wilson Elser.

  • Tips From Del. Decision Nixing Major Earnout Damages Award

    Author Photo

    The Delaware Supreme Court recently vacated in part the largest earnout-related damages award in Delaware history, making clear that the implied covenant of good faith and fair dealing cannot be used to rescue parties from drafting choices where the relevant regulatory risk was foreseeable at signing, say attorneys at Sullivan & Cromwell.

  • USPTO's New Patentability Focus Helps Emerging Tech

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to shift patentability criteria back toward traditional standards of novelty, obviousness and adequate disclosure should make it easier for emerging tech, including artificial intelligence, to obtain patents, says Bill Braunlin at Barclay Damon.

  • Malpractice Claim Assignability Continues To Divide Courts

    Author Photo

    Recent decisions from courts across the country demonstrate how different jurisdictions balance competing policy interests in determining whether legal malpractice claims can be assigned, providing a framework to identify when and how to challenge any attempted assignment, says Christopher Blazejewski at Sherin & Lodgen.

  • Courts' Rare Quash Of DOJ Subpoenas Has Lessons For Cos.

    Author Photo

    In a rare move, three federal courts recently quashed or partially quashed expansive U.S. Department of Justice administrative subpoenas issued to providers of gender-affirming care, demonstrating that courts will scrutinize purpose, cabin statutory authority and acknowledge the profound privacy burdens of overbroad government demands for sensitive records, say attorneys at ArentFox Schiff.

  • Unpacking Dormant Commerce Clause Cannabis Circuit Split

    Author Photo

    Federal courts have reached differing conclusions as to whether state-legal cannabis is subject to the dormant commerce clause, with four opinions across three circuit courts in the last year demonstrating the continued salience of the dormant commerce clause debate to the nation's cannabis industry, regulators and policymakers, say attorneys at Perkins Coie.

  • Opinion

    CFIUS Must Adapt To Current Foreign Investment Realities

    Author Photo

    To continue protecting the U.S.’ long-term strategic and economic interests, the Committee on Foreign Investment in the United States should implement practical enhancements that leverage technology, expertise and clear communication, and enable it to keep pace with evolving demands, says attorney Sohan Dasgupta.

  • Utah's AI Prescription Renewal Pilot Could Inform Policy

    Author Photo

    Utah recently became the first state to approve an artificial intelligence system for autonomously renewing certain prescription medicines, providing a test case for how regulators may be able to draw boundaries between administrative automation and medical judgment, say Jashaswi Ghosh at Holon Law Partners and Bryant Godfrey at Foley Hoag.

  • Ramped Up Psychedelic Production Carries Opportunity, Risk

    Author Photo

    Kimberly Chew at Husch Blackwell discusses the key legal implications of the U.S. Drug Enforcement Administration's recent dramatic increases in the production quotas for a range of psychedelic substances, offering guidance on compliance, risk management and strategic opportunities for practitioners navigating this rapidly evolving landscape.

  • Series

    Teaching Logic Makes Me A Better Lawyer

    Author Photo

    Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.

  • New Biotech Nat'l Security Controls May Have Blunted Impact

    Author Photo

    While the newly enacted federal prohibition against contracting with certain biotechnology providers associated with countries of concern may have consequences on U.S. companies' ability to develop drugs, the restrictions may prove to be less problematic for the industry than the significant publicity around their passage would suggest, say attorneys at Wilson Sonsini.

  • From IPR To EPR: The Rapid Rise Of Ex Parte Reexamination

    Author Photo

    With the current administration's dramatic shifts in policy rendering inter partes reviews essentially unavailable for the majority of patents being asserted in litigation, IPR filing rates have plunged, and ex parte reexamination requests have surged to the average rate of IPR petitions in 2024, say attorneys at McKool Smith.

  • Series

    Law School's Missed Lessons: Practicing Resilience

    Author Photo

    Resilience is a skill acquired through daily practices that focus on learning from missteps, recovering quickly without internalizing defeat and moving forward with intention, says Nicholas Meza at Quarles & Brady.

  • Takeaways From The DOJ Fraud Section's 2025 Year In Review

    Author Photo

    Former acting Principal Deputy Chief Sean Tonolli of the U.S. Department of Justice's Fraud Section, now at Cahill Gordon, analyzes key findings from the section’s annual report — including the changes implemented to adapt to the new administration’s priorities — and lays out what to watch for this year.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.